Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Hess, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, Carlo Visco, Jan Walewski, Francesco Zaja, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review

11 Citations (SciVal)

Abstract

Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.

Original languageEnglish
Pages (from-to)1814-1828
JournalLeukemia and Lymphoma
Volume59
Issue number8
Early online date2017 Nov 27
DOIs
Publication statusPublished - 2018

Subject classification (UKÄ)

  • Cancer and Oncology

Keywords

  • Chemotherapy
  • clinical trials
  • mantle cell lymphoma
  • molecular targeted therapy

Fingerprint

Dive into the research topics of 'Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations'. Together they form a unique fingerprint.

Cite this